Production (Stage)
Rakovina Therapeutics Inc.
RKV.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 464.50K | 197.20K | 201.80K | 186.20K | 177.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 996.40K | 694.50K | 552.50K | 511.80K | 486.20K |
| Operating Income | -996.40K | -694.50K | -552.50K | -511.80K | -486.20K |
| Income Before Tax | -1.06M | -744.70K | -599.70K | -558.10K | -531.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.06M | -744.70K | -599.70K | -558.10K | -531.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.06M | -744.70K | -599.70K | -558.10K | -531.30K |
| EBIT | -996.40K | -694.50K | -552.50K | -511.80K | -486.20K |
| EBITDA | -899.90K | -595.40K | -454.80K | -412.70K | -386.90K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 100.22M | 89.67M | 70.71M | 70.08M | 69.91M |
| Average Diluted Shares Outstanding | 100.22M | 89.67M | 70.71M | 70.08M | 69.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |